JPRN-jRCT2080222140未知1 期
A clinical pharmacology study of CH5424802 in patients with ALK-positive NSCLC
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •-ECOG PS 0-1
- •-ALK-positive
排除标准
- •-Prior treatment with CH5424802
- •-Meningeal metastases or brain metastases that are symptomatic or requiring treatment
- •-Pregnatnt or lactating women
研究者
相似试验
进行中（未招募）
1 期
Phase II study of oral PHA-848125AC in patients with thymic carcinoma previously treated with chemotherapyRecurrent or metastatic unresectable thymic carcinomaEUCTR2009-014338-79-FRerviano Medical Sciences S.r.l.60
进行中（未招募）
1 期
Study of oral PHA-848125AC in patients with malignant thymoma previously treated with multiple lines of chemotherapyRecurrent or metastatic, unresectable B3 thymoma or thymic carcinoma previously treated with multiple lines of chemotherapyEUCTR2013-000344-25-ITerviano Medical Sciences S.r.l.30
招募中
1 期
Clinical Pharmacology Study of EPI-589Amyotrophic lateral sclerosisJPRN-jRCT2071210023Hamatani Tatsuto40
进行中（未招募）
1 期
A CLINICAL PHARMACOLOGY STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF NXT007 WITH A NEW PREPARATION METHOD IN HEALTHY JAPANESE MALE ADULTSHemophilia AJPRN-jRCT2031220050Takehiko Sambe30
进行中（未招募）
1 期
Clinical and pharmacokinetic phase II study of one hour infusion of kahalalide F administered every week to patients with Non Small Cell Lung Cancer Stage IIIB with pleural effusion and stage IV, after first line chemotherapyon Small Cell Lung Cancer Stage IIIB and IV after first Line ChemotherapyMedDRA version: 5.0Level: LLTClassification code 10029514EUCTR2004-001253-29-ESPharmaMar SA34